

## ASX Announcement

### Retirement of Chief Medical Officer

---

**Sydney, Australia, 21 January 2022:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, today announces a change to a key management role.

Imugene's Chief Medical Officer (CMO) Dr Rita Laeufle will be retiring from her role and the Company at the end of January Dr Laeufle has played an important role in advancing Imugene's clinical efforts and the board thanks her for her important contributions to the Company.

Imugene is in the final negotiation to bring in a high calibre oncologist and clinical developer as a CMO to further strengthen its experienced executive team, the company will update the market on this appointment at a later time.

"We thank Dr Laeufle for her valuable contribution over the past 16 months and wish her well in her retirement ", said Imugene's CEO Leslie Chong.

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
info@imugene.com

**Investor Enquiries**  
investor@imugene.com

**Media Enquiries**  
Matt Wright  
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited

### About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard

of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immunology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*

*Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*